Percutaneous coronary intervention in a patient with heparin resistance due to essential thrombocythaemia: a case report
Open Access
- 28 February 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 5 (3) , ytab087
Abstract
Coronary artery disease is uncommon in patients with essential thrombocythaemia (ET); therefore, no treatment strategies have been established. A 68-year-old man visited our hospital with worsening effort angina complicated with ET. Coronary angiography (CAG) revealed moderate stenosis of the left main trunk and left anterior descending artery (LAD). We planned to perform percutaneous coronary intervention (PCI) only after the patient’s platelet count had fallen below 600 000/μL. Platelet factor 4 levels were markedly elevated (355.0 ng/mL; the normal range is de novo lesion in the proximal left circumflex artery and stenosis progression in the LAD at the time of the PCI, neither of which had been detected at the previous CAG. During the PCI procedure, argatroban was infused to maintain the activated clotting time (ACT) above 250 s. The PCI was performed successfully without any complications. Follow-up CAG showed no restenosis, and no bleeding complications were observed during the course. In patients with ET, it may be useful to measure platelet factor 4 before PCI and to monitor ACT during the procedure. When heparin resistance is suspected based on blood coagulation tests, infusion of direct thrombin inhibitor during PCI may be considered, with anticoagulation monitoring by ACT.Keywords
This publication has 16 references indexed in Scilit:
- Essential Thrombocythemia and Cardiac Surgery: A Case Series and Review of the LiteratureThe Annals of Thoracic Surgery, 2018
- Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia veraThe Anatolian Journal of Cardiology, 2016
- Heparin-Induced Thrombocytopenia in a Patient with Essential Thrombocythemia: A Case Based UpdateCase Reports in Hematology, 2015
- Argatroban in Extracorporeal Membrane OxygenationArtificial Organs, 2007
- Clinical and Laboratory Features, Pathobiology of Platelet-Mediated Thrombosis and Bleeding Complications, and the Molecular Etiology of Essential Thrombocythemia and Polycythemia Vera: Therapeutic ImplicationsSeminars in Thrombosis and Hemostasis, 2006
- Hydroxyurea Compared with Anagrelide in High-Risk Essential ThrombocythemiaNew England Journal of Medicine, 2005
- Argatroban Anticoagulation in Patients With Heparin-Induced ThrombocytopeniaArchives of internal medicine (1960), 2003
- Platelet Factor 4 Enhances the Binding of Oxidized Low-density Lipoprotein to Vascular Wall CellsJournal of Biological Chemistry, 2003
- The mechanism of action of thrombin inhibitors.2000
- Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.Journal of Clinical Oncology, 1990